Morepen Laboratories Ltd
About
Morepen Laboratories is an Indian pharmaceutical company headquartered in Gurugram and led by Sushil Suri. Among 4 manufacturing facilities, its unit at Baddi houses 10 plants, each tailored to produce a specific product line. Through its brands—Dr. Morepen and Gubb World—Morepen offers over 800 active pharmaceutical ingredients (APIs), formulations, over-the-counter and healthcare products, along with diagnostic services. With regulation certificates from global authorities such as the Food and Drug Administration (FDA) of the US and the World Health Organisation’s good manufacturing practice (GMP), Morepen distributes its products to 82 countries all over the world. Its R&D activities have helped the company gain over 33 patents and file for another 60. Morepen is currently developing more than 25 new molecules to expand its efficacy in the healthcare sector.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 1702 21.0% | 1407 -10.2% | 1567 26.2% | 1242 42.3% | 873 10.2% | 792 30.5% | 607 -1.3% | 614 25.3% | 490 22.2% | 401 8.6% | 369 12.0% | 330 7.4% | 307 32.0% | 233 -7.3% | 251 28.5% | 195 - |
| Net Operating Income (INR Cr) | 1690 19.25% | 1418 -8.36% | 1547 30.20% | 1188 39.27% | 853 11.00% | 769 26.72% | 607 1.85% | 595 22.75% | 485 21.08% | 401 9.21% | 367 12.56% | 326 12.64% | 289 26.74% | 228 9.69% | 208 14.93% | 181 25.21% |
| Profit (INR Cr) | 96 148.6% | 39 -62.0% | 102 4.7% | 97 189.1% | 34 16.4% | 29 -2.5% | 30 25.2% | 24 84.6% | 13 498.1% | 2 - | -3 - | -21 - | -24 - | -47 - | -6 - | -42 - |
| Assets (INR Cr) | 915 12.8% | 811 29.1% | 628 33.5% | 471 5.9% | 444 9.5% | 406 7.7% | 377 -1.0% | 381 -0.1% | 381 0.4% | 380 -4.1% | 396 -5.7% | 420 -6.3% | 448 -7.2% | 483 -8.9% | 530 -7.4% | 573 - |
| Net Worth (INR Cr) | 847 12.5% | 753 30.1% | 579 36.2% | 425 49.5% | 284 12.2% | 253 12.0% | 226 15.1% | 196 8.7% | 181 7.6% | 168 -5.4% | 177 -1.5% | 180 -10.2% | 201 -10.5% | 224 -17.3% | 271 57.0% | 173 -22.0% |
| Employee Cost (INR Cr) | 181 17.3% | 155 -5.8% | 164 21.1% | 136 23.4% | 110 15.3% | 95 24.6% | 77 9.8% | 70 19.6% | 58 19.5% | 49 8.2% | 45 13.6% | 40 8.5% | 37 18.0% | 31 32.0% | 24 12.8% | 21 - |
| Interest Cost (INR Cr) | 4 | 2 | -7 | 2 | 2 | 2 | 4 | 8 | 11 | 9 | 10 | 12 | 8 | 6 | 4 | 3 |
| Cash & Bank Balance (INR Cr) | 52 | 56 | 46 | 68 | 39 | 32 | 6 | 8 | 4 | 9 | 9 | 6 | 5 | 3 | 1 | 5 |
| Total Debt (INR Cr) | 29 | 25 | 19 | 17 | 133 | 132 | 134 | 169 | 68 | 81 | 89 | 111 | 121 | 133 | 140 | 280 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 5.7% | 2.8% | 6.5% | 7.8% | 3.9% | 3.6% | 4.9% | 3.9% | 2.6% | 0.5% | - | - | - | - | - | - |
| Profit As % Of Assets | 10.5% | 4.8% | 16.2% | 20.6% | 7.6% | 7.1% | 7.9% | 6.2% | 3.4% | 0.6% | - | - | - | - | - | - |
| Profit As % Of Networth | 11.4% | 5.1% | 17.6% | 22.9% | 11.8% | 11.4% | 13.1% | 12.0% | 7.1% | 1.3% | - | - | - | - | - | - |
| Interest Cost to EBITDA % | 2.3% | 2.5% | - | 1.5% | 2.9% | 3.1% | 6.7% | 12.3% | 18.4% | 18.0% | 20.3% | 37.6% | 41.4% | 108.7% | 51.0% | 246.3% |
| Debt to Equity Ratio | 0.03 | 0.03 | 0.03 | 0.04 | 0.47 | 0.52 | 0.59 | 0.86 | 0.37 | 0.48 | 0.50 | 0.62 | 0.60 | 0.59 | 0.52 | 1.62 |
| RONW | 12.1% | 5.8% | 20.3% | 25.9% | 10.2% | 8.7% | 9.0% | 7.1% | 5.2% | 0.8% | - | - | - | - | - | - |
| ROCE | 16.1% | 8.0% | 21.7% | 20.9% | 8.5% | 6.5% | 6.8% | 6.0% | 5.1% | 2.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |